股价：13.28 港元 主要数据 | 行业 | 医药 | | --- | --- | | 公司网址 | www.cms.net.cn | | 大股东/持股 | Treasure Sea Limited | | 实际控制人 | 林刚 | | 总股本(百万股) | 2439.53 | | 流通 B/H 股(百万股) | 2439.53 | | 总市值（亿港元） | 324 | 行情走势图 业绩重回上升轨道，潜力大单品迎来收获期 推荐（首次） 医药 2025 年 12 月 4 日 康哲药业(0867.HK) 证券分析师 | 叶寅 | 投资咨询资格编号 | | --- | --- | | | S1060514100001 | | | BOT335 | | | YEYIN757@pingan.com.cn | | 韩盟盟 | 投资咨询资格编号 | | | S1060519060002 | | | hanmengmeng005@pingan.com.cn | | 张梦鸽 | 投资咨询资格编号 | | | S1060525070003 | | | ZHANGMENGGE752@pingan.com.cn | 平安观点： | ...

Core Insights - The report maintains a "stronger than market" rating for the real estate sector, indicating a positive outlook despite ongoing challenges in the market [1] - The real estate market in 2025 is characterized by an initial recovery followed by a decline, with high inventory levels and weak demand impacting overall performance [4][13] - The report anticipates that the supportive policies for the real estate market will continue into 2026, although market confidence will take time to recover [4][5] Market Review - In 2025, the national real estate market experienced a decline in sales, with a 9.6% year-on-year drop in sales amount from January to October, although the decline was less severe than in 2024 [13] - The second-hand housing market outperformed the new housing market, with a reported 8% increase in transactions for the top ten cities compared to a 10.5% decline in new homes [13][46] - The overall market remains in an adjustment phase, with supply-demand relationships still needing improvement [13] 2026 Outlook - Positive factors are expected to converge, leading to a gradual stabilization of the real estate market, particularly in core urban areas and quality housing [4][5] - The report predicts a 6% decline in sales area and an 8.5% decline in investment for 2026, reflecting ongoing market pressures [4][5] Investment Opportunities - The demand for "good houses" is projected to grow, with an average annual improvement demand of 590 million square meters from 2025 to 2030, representing 67% of total demand [4] - Quality real estate companies with strong land acquisition and product capabilities are expected to benefit first from the "good house" trend, with companies like China Overseas Development and China Resources Land highlighted as potential beneficiaries [5][6] - The Hong Kong real estate market is showing signs of stabilization, with a 20.3% year-on-year increase in transaction volume for the first ten months of 2025, presenting investment opportunities for Hong Kong-based real estate firms [4][5][52] Key Company Forecasts - The report includes earnings forecasts for several key companies, indicating a positive outlook for firms like Poly Developments and China Overseas Development, with expected earnings per share (EPS) growth over the next few years [6][7] - Companies with stable cash flow and dividends, such as China Resources Vientiane Life and Poly Property, are also recommended for investment consideration [5][6]

证券研究报告 医保基金数据跟踪：10月居民医保收入下降， 支出增加 医药行业 强于大市（维持） 证券分析师 叶寅 投资咨询资格编号:S1060514100001 邮箱：YEYIN757@PINGAN.COM.CN 倪亦道 投资咨询资格编号:S1060518070001 邮箱：NIYIDAO242@PINGAN.COM.CN 王钰畅 投资咨询资格编号:S1060524090001 邮箱：WANGYUCHANG804@PINGAN.COM.CN 2025年12月3日 请务必阅读正文后免责条款 核心观点 2025年1-10月统筹医保基金收入维持正增长，且收入大于支出。2025年1-10月收入为23520.10亿元，同比增长1.97%，2025年1-10月支出 为19036.24亿元，同比下降0.68%。除5月外，统筹医保基金收入均大于支出，累计统筹医保基金2025年1-10月呈增长趋势。2025年1-10 月，统筹医保基金结余共计4483.86亿元，同比增长14.99%。结余率方面，2025年1-10月结余率为19.06%，同比2024年1-10月提升2.15pp， 2025年单10月结余率为27.84%，2025 ...

Investment Rating - The report maintains an "Outperform" rating for the biopharmaceutical industry [1] Core Viewpoints - The development of commercial health insurance is supported by favorable policies, with significant potential for capital inflow. Since 2009, policies have continuously supported the establishment of a multi-level medical security system and the development of commercial health insurance. The sharing of medical insurance data with commercial insurance companies is entering a practical phase, which is expected to improve the insurance landscape [2][28] - The commercial health insurance sector is projected to reach a compensation scale of approximately 471.57 billion yuan by 2030 under neutral expectations, indicating substantial potential for the medical industry [31][32] Summary by Sections Part 1: Commercial Health Insurance is Flourishing, Compensation Growth is Expected - The demand side emphasizes the impact of premium pricing and the insurance needs of patients with pre-existing conditions and the elderly. The increase in disposable income and policies allowing the use of personal medical insurance accounts for purchasing health insurance are expected to enhance insurance uptake [11][12][29] - The supply side highlights the importance of product design in health management, special drug coverage, and deductible settings. Enhancements in these areas can attract more policyholders and improve profitability [20][21][28] Part 2: Current Situation: Insufficient Motivation for Innovative Drug and Device Use - The DRG payment system has reduced the motivation for hospitals to use innovative drugs and devices, necessitating the exploration of alternative payment sources. High-level hospitals face greater pressure under the DRG system, which may hinder the adoption of innovative treatments [35][39] Part 3: Commercial Insurance Development Benefits Innovative Drugs and DTP Pharmacies - The commercial health insurance sector is increasingly covering innovative drugs, with payments rising from 1.1 billion yuan in 2020 to 2.2 billion yuan in 2023, reflecting a compound annual growth rate of 27.8%. The penetration rate for commercial health insurance in the innovative drug market remains low, indicating significant room for growth [67][68] - DTP pharmacies are emerging as a crucial channel for the distribution of innovative drugs, providing a pathway for patients to access high-value medications outside of traditional hospital settings [76][80] Part 4: Innovative Devices May Benefit from Commercial Insurance Development - Innovative medical devices, particularly those not fully covered by insurance, are expected to benefit from commercial insurance. The report suggests that high-value medical devices and certain surgical procedures may gain traction in the commercial insurance market [4][81] Part 5: Investment Recommendations - The report recommends focusing on companies with rich pipelines in innovative drugs, such as Heng Rui Medicine and BeiGene, as well as DTP pharmacies and TPA (Third Party Administrator) companies that are well-positioned to benefit from the growth of commercial health insurance [4][81]

Market Review - The A-share market is gradually forming a slow bull trend, with technology growth as the main driver. As of November 28, 2025, the Shanghai Composite Index, ChiNext Index, and Sci-Tech 50 Index have increased by 16.0%, 42.5%, and 34.2% respectively, with sectors such as non-ferrous metals, telecommunications, and power equipment leading the gains [10][15][18]. Market Environment - The external economic environment is expected to recover moderately, with the U.S. potentially entering a phase of "loose monetary + loose fiscal" policies. This is likely to sustain technology investment and maintain resilient consumer spending [23][24]. - Domestic new growth drivers continue to strengthen, with corporate profit expectations improving. The "14th Five-Year Plan" emphasizes economic construction, and fiscal policies are expected to support technology innovation, livelihood security, and infrastructure investment [23][31]. - A-share corporate profitability is anticipated to continue improving, with certain industries such as military industry, power equipment, TMT (Technology, Media, and Telecommunications), pharmaceuticals, non-ferrous metals, and steel expected to see upward trends in profitability [23][26]. Structural Opportunities - The "14th Five-Year Plan" outlines four major industrial directions, with technology and manufacturing as dual cores leading the way. Key areas include: 1. **Technology Innovation**: Focus on high-level technological self-reliance and nurturing emerging industries, with AI as a core investment theme. Global AI capital expenditure is expected to grow significantly, supporting high prosperity in related industries [23][31]. 2. **Advanced Manufacturing**: Strengthening the global leading position in advantageous manufacturing sectors, particularly in new energy and defense industries, which are expected to benefit from national security demands and military trade upgrades [23][31]. 3. **Domestic Circulation**: Building a strong domestic market to boost consumption and address internal competition issues. Policy support is expected to release new consumer demand potential [23][31]. 4. **Resource Security**: Enhancing the protection and utilization of strategic resources, with macroeconomic and fundamental resonance likely to drive up non-ferrous metal prices [23][31]. Market Outlook - The report suggests focusing on four main lines for investment opportunities: 1. **Technology Innovation**: Emphasizing the AI industry chain, including semiconductors, communications, PCB, applications, and robotics [23][31]. 2. **Advanced Manufacturing**: Paying attention to new energy and defense industries [23][31]. 3. **Upstream Cycles**: Monitoring price signals in non-ferrous metals and chemicals [23][31]. 4. **Domestic Consumption**: Focusing on new consumption trends [23][31].

证券研究报告 公募REITs三季报： 整体符合预期，稳定优于周期 ※ 核心观点 注：此前我们对解禁的专题研究，见平安固收团队《证券转向超配产业园，未来关注解禁带来的配置机会》20250917 2 • 25Q3季报符合预期，稳定/周期之间有分化。剔除扩募扰动后，25Q3季报收入同比-4%（本文无特殊说明的，均为25Q3数据）。收入、 可供分配完成度分别为95%、98%，边际均有所上行。结构上，延续周期板块下行、稳定板块稳健增长的趋势。按业绩由好至弱，叠加 考虑业绩强弱的延续性，可分为三个梯队，保障房、消费＞经营权＞产业园、仓储。 • 稳定板块：保障房、消费延续稳健增长。剔除扩募扰动后，保障房出租率波动不大。消费收入同比+4%。两个板块剔新券后的收入、可 供分配金额完成度均在100%以上，在各板块中处于较高水平。 • 经营权类延续宽幅波动。正向波动的是环保，收入完成度均达标，且富国首创水务可供分配金额完成度在130%以上。负向波动的主要 是交通、能源、水利。经营权波动多与水光风资源、路网变动等因素有关，一般来说是短期扰动。相对值得跟踪的长期变化是能源的电 力市场化，从25Q3季报来看，各项目电力市场化交易进度有差 ...

1. Report Industry Investment Rating No industry investment rating information is provided in the report. 2. Report's Core View - The recovery signal of the fundamental situation still needs to be observed, the momentum factor remains bearish, and the market sentiment is rising from a low level. It is recommended to maintain an under - allocation of equity assets. In the short - term style, the small - cap style is expected to dominate in December, and the growth style will continue to dominate. It is recommended to focus on small - cap and growth styles. For fixed - income + funds, it is recommended to focus on relatively stable varieties, and for bond funds, focus on short - duration varieties [2][74]. 3. Summary According to the Catalog 11 - month Review Stock Market - A - shares declined, with the Shanghai Composite Index falling 1.67% and the Science and Technology Innovation 50 falling 6.24%. The Dow Jones Index rose 0.32%, and the Nasdaq Index fell 1.51%. Affected by concerns about the valuation of the US stock AI sector and the volatility of the Fed's interest - rate cut expectations, A - shares and Hong Kong stocks declined, and US stocks fluctuated [8][13]. Bond Market - US bond yields declined, with the 1 - year US bond yield dropping to 3.61% and the 10 - year US bond yield dropping to 4.02%. Domestic bond yields rose, with the 1 - year Treasury yield rising to 1.40% and the 10 - year Treasury yield rising to 1.84%, and the term spread widened. The decline in US bond yields was due to the volatility of the Fed's interest - rate cut expectations, while the rise in domestic bond yields was because the central bank's Treasury purchase volume was lower than expected [8][17]. Foreign Exchange Market - The US dollar index declined to 99.44, and the RMB appreciated. The on - shore exchange rate of the US dollar against the RMB rose to 7.08, and the off - shore exchange rate rose to 7.07. The decline in the US dollar index was due to the continuous volatility of the Fed's interest - rate cut expectations, and the RMB appreciation was supported by the weakening of the US dollar and the strong domestic economic fundamentals [20]. Commodity Market - Crude oil prices fell to $63.2 per barrel. Domestic commodity prices rose slightly after fluctuations, and overseas commodity prices fell overall after rising first and then falling. Among domestic commodities, precious metals and grains led the gains, while coal, coking, steel, minerals, agricultural and sideline products, non - metallic building materials, non - ferrous metals, energy, and chemicals declined [25]. Fund Market - The performance of the fund market in November was poor. The issuance scale increased to 94.6 billion yuan, a 31% increase from the previous month. Structurally, the issuance scale of equity funds was 45.3 billion yuan, a 30% increase from the previous month, accounting for 48% of the total issuance. ETF funds had a net inflow of 100.9 billion yuan (excluding money funds), and LOF funds had a net outflow of 320 million yuan. Among them, equity - type ETF products had a net inflow of 32.3 billion yuan, and equity - type LOF products had a net outflow of 440 million yuan. Active equity funds increased their positions in dividend, value - potential, and prosperous styles and reduced their positions in quality styles [30][36][37]. 12 - month Outlook Overseas Environment - The market's expectation of the Fed's interest - rate cut within the year fluctuated significantly, and the market expected the Fed to cut interest rates in December. The probability of the Fed cutting interest rates in December increased to over 80%. US bond yields first rose and then fell, with an overall decline [43]. Domestic Environment - The private - sector financing growth rate continued to decline, and the inflation factor rebounded from a low level. It is recommended to maintain an under - allocation of equity assets as the economic recovery signal still needs to be observed, and the momentum factor remains bearish [47]. Trading Perspective - The stock - market odds were close to the three - year average, and the A - share market sentiment was rising from a low level but had not yet returned to the optimistic range [48][52]. Market Style - The growth - value style rotation model shows that the market factor, US bond yield, and style momentum are all favorable for growth, and the growth style will continue to dominate. The small - large - cap style rotation model shows that the current credit environment, monetary environment, and long - and short - term style momentum all recommend the small - cap style [59][64]. Hong Kong Stock Market - The number of macro - indicators bullish on Hong Kong stocks decreased compared with last month. The model recommends an under - allocation of Hong Kong stocks as the private - sector financing growth rate, Hong Kong dollar M2 growth rate, and Chinese sovereign CDS spread are bearish, although the US dollar index and south - bound funds are bullish [68]. Domestic Bond Market - Short - term liquidity remained in a tight balance, and long - term interest rates rose. It is recommended to focus on short - duration bond funds as short - term bonds have better opportunities than long - term bonds [71]. Fund Allocation Strategy - It is recommended to maintain an under - allocation of equity assets and focus on small - cap and growth styles. For fixed - income + funds, focus on relatively stable varieties, and for bond funds, focus on short - duration varieties. Recommended funds include Dongwu Mobile Internet (001323.OF, medium - high risk), CITIC Prudential Multi - Strategy (165531.OF, medium - high risk), Harvest New Consumption (001044.OF, medium - high risk), BOC Steady Income (380009.OF, medium risk), and Penghua Stable Short - Term Bond (007515.OF) [2][74].

Investment Rating - The report maintains a "Strong Buy" rating for the renewable energy sector, particularly highlighting the wind and solar segments as outperforming the market [2]. Core Insights - The report emphasizes the significant contracts emerging in the energy storage supply chain, with Longi signing a major project in the Middle East for BC components, indicating strong international demand [6][7]. - The wind power index has shown a 4.06% increase, outperforming the CSI 300 index by 2.42 percentage points, reflecting a positive market sentiment [5][11]. - The report notes that the domestic wind turbine bidding prices are stabilizing, which is expected to improve the profitability of turbine manufacturers [7]. Summary by Sections Wind Power - The Waning Floating Project has completed its cable procurement, with the project expected to be operational by 2027, marking a significant milestone in China's offshore wind development [10]. - The wind power index has increased by 4.06% this week, with a current PE_TTM valuation of approximately 25.13 times [11]. - Key companies in the wind sector, such as Goldwind Technology and Mingyang Smart Energy, are recommended for investment due to their expanding overseas markets and improving profitability [7][15]. Solar Power - Longi Green Energy has signed a cooperation agreement for a 1.5GW solar project in Abu Dhabi, showcasing its competitive edge in both domestic and international markets [6]. - The solar equipment index has risen by 4.18%, with the current PE_TTM valuation around 44.19 times, indicating strong market performance [5]. Energy Storage & Hydrogen - The energy storage supply chain is witnessing large-scale contracts, with Dragon Power Technology and Chuangneng New Energy agreeing to a significant procurement deal, highlighting the trend of securing supply chains amid rising demand [7]. - The energy storage index has increased by 4.79%, with a current PE_TTM of 30.73 times, reflecting a robust market outlook [5]. - Companies like Sungrow Power and Haibo Technology are recommended for their strong market positions and growth potential in the energy storage sector [7].

Economic Growth Outlook - The GDP growth target for China in 2026 is expected to remain around 5%[4] - The contribution of final consumption expenditure to GDP growth is projected to be 53.5% in 2025, up from 44.5% in 2024[26] - The anticipated growth rate of social retail sales is around 4% in 2026, with final consumption expenditure growth expected to exceed 5%[51] Export Performance - China's export share is projected to continue its upward trend, with an expected growth rate of 4-5% in 2026[21] - As of July 2025, China's export share reached 15.1%, up from 14.9% in 2024, indicating strong global competitiveness[14] Investment Stability - Real estate investment is expected to stabilize, with a projected decline of around 10.2% in 2026, a significant improvement from previous years[55] - Infrastructure investment growth is anticipated to rebound significantly in 2026, supported by new policy tools and long-term special bonds[74] Inflation and Price Trends - CPI is expected to rise to around 0.6% in 2026, driven by food prices, while PPI is projected to recover from a decline of -2.8% in 2025[95][116] - The core CPI is expected to maintain a higher level of around 0.8-1% in 2026, reflecting improved consumer confidence and spending[110] Fiscal Policy Outlook - The narrow deficit ratio is projected to increase to 4-4.3% in 2026, with a special bond issuance of approximately 1.5 trillion yuan[127] - New local special bonds are expected to be in the range of 5-5.5 trillion yuan, marking an increase from 2025[128]

Investment Rating - The report maintains an "Outperform" rating for the industry [2]. Core Insights - The third-generation EGFR TKI has become the first-line standard therapy for advanced EGFR mutation NSCLC, significantly extending median progression-free survival (mPFS) to 18.9-22.1 months compared to earlier generations [4][24]. - The domestic EGFR TKI market is expected to exceed 20 billion CNY in 2024, with third-generation EGFR TKIs accounting for 88% of the market share [4][30]. - There is an urgent need to address resistance mechanisms following third-generation EGFR TKI treatment, with ongoing exploration of fourth-generation TKIs, bispecific antibodies, and antibody-drug conjugates (ADCs) [5][32]. Summary by Sections 1. High Incidence of Lung Cancer in China - Lung cancer is the most common malignant tumor globally, with approximately 2.6 million new cases expected in 2024, including about 1.15 million in China [8]. - Non-small cell lung cancer (NSCLC) accounts for around 85% of lung cancer cases, with adenocarcinoma and squamous cell carcinoma being the most prevalent subtypes [8]. 2. Third-Generation EGFR TKI as First-Line Therapy - The third-generation EGFR TKI has established itself as the first-line treatment for advanced EGFR mutation NSCLC, with significant improvements in mPFS compared to first and second generations [4][16][24]. - The report highlights the efficacy of third-generation TKIs in overcoming common mutations and their favorable safety profile [4][24]. 3. Exploration of Resistance Mechanisms - The report discusses the complexity of resistance mechanisms to third-generation EGFR TKIs, including both EGFR-dependent and independent pathways [5][32]. - Current research focuses on developing fourth-generation TKIs targeting specific mutations and exploring combination therapies with bispecific antibodies and ADCs [5][32][39]. 4. Investment Recommendations - The report emphasizes the growth potential of third-generation EGFR TKIs and suggests monitoring companies like Hansoh Pharma and Eli Lilly for market penetration and sales growth [51]. - It also highlights the progress of ADCs and bispecific antibodies in clinical trials, indicating a robust pipeline for future treatments [51][52].